Retatrutide, a novel dual stimulator of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising data in early patient studies. Ongoing research indicates https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/